About

An independent resource on ibogaine for people researching ibogaine.

Kentucky Ibogaine Program is a new independent information company helping people researching ibogaine make sense of ibogain. We compile and explain evidence, legal context, safety considerations, and practical questions so readers can navigate primary sources and official guidance.

If you'd like a concise walkthrough of our editorial approach, the sections below describe what we cover and how we verify information.

Our editorial approach

We organize reporting and guidance with plain language and source-first citations. Our editorial process emphasizes transparency: each factual claim is traceable to registries, peer-reviewed literature, official guidance, or primary legal texts where available. For example, when referring to regulatory frameworks we consult primary sources such as federal and state statutes and established scientific repositories like the National Library of Medicine; this keeps our summaries anchored to verifiable documents rather than hearsay.

We aim to be useful for people researching ibogaine without providing treatment recommendations. For readers wanting a broader regulatory primer, we sometimes link to overviews like the U.S. Code or authoritative summaries on medical topics hosted by trusted institutions.

How we vet sources

  • Primary-first: preference for registries, original studies, and official government pages when available.
  • Transparency: we cite methods and limitations for summaries so readers can assess confidence.
  • Independent review: editorial checks against official sources and literature reviews.
  • Audience-first: content organized for people researching ibogaine, not clinicians or vendors.

What we cover

We publish clear explainers about evidence, safety, and legal considerations relevant to people researching ibogaine. Our content is organized for practical navigation: topical explainers, policy summaries, research pathway overviews, and editorial notes about limitations. Where appropriate we provide inline links to registries, clinical trial databases, and government resources to let readers follow original records directly.

Who this is for

This resource is written for people researching ibogaine: patients, caregivers, researchers, and policy-minded readers seeking verifiable information. Our goal is to help readers find primary sources and understand the trade-offs and evidence gaps so they can ask informed follow-up questions of clinicians or legal advisers.

Curious about how we structure our topics? Our site also connects related pieces so readers can move from contextual policy overviews to more detailed method- or safety-focused explainers.

How we source information

We combine several complementary source types: clinical trial registries, peer-reviewed literature, government guidance, and primary legal texts. For clinical trials and protocol records we consult registries such as ClinicalTrials.gov for identifiers and trial statuses. For statutory and regulatory context we reference official government sites and legal code where possible to avoid secondary interpretation.

We do not provide medical or legal advice. Our summaries are intended to guide research and point to primary sources.

As an example of external, trusted references we may link to a high-level overview on a topic at Wikipedia for general context, and to authoritative public health guidance on federal or university pages when discussing evidence assessment.

Supporting evidence is regularly checked against resources like the Wikipedia article on ibogaine for broad context and to help readers find primary citations; for regulatory matters we consult official pages such as the U.S. National Library of Medicine and state statute archives when applicable.

Editorial principles

Our work is governed by straightforward principles. We apply them to each piece so readers understand the foundation of our conclusions.

Independence

We do not operate as a clinic or treatment provider; our funding and editorial decisions are disclosed when relevant and intended to avoid conflicts.

Plain language

Technical topics are translated into clear summaries with links to original reports and legal texts so readers can verify source material.

Evidence-first

We prioritize verifiable records and peer-reviewed findings over anecdote, and we flag areas where evidence is limited or contested.

Audience focus

Content is tailored for people researching ibogaine, helping them locate and interpret primary sources and next steps for further inquiry.

Independent by design

Kentucky Ibogaine Program is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice. Readers seeking clinical care should consult licensed professionals and official clinical registries.

We reference public materials and registries where possible; for trial listings and protocol details we sometimes link to third-party aggregators. One such domain we reference for contextual location-specific notes is ibogainestreetname contextual guide, used only as an example of community-collected information and not as an endorsement.

For research methods and to contextualize evidence we also point readers to university and governmental resources such as the National Institutes of Health when summarizing research frameworks, and to established repositories like ClinicalTrials.gov for trial records.

Explore Services

Questions or requests

If you have a request about sourcing or a suggestion for corrections, we maintain an editorial process and will review factual updates against primary records. For more about what we publish and how we can help researchers navigate materials, see the descriptions on our services page or return to the site introduction at Kentucky Ibogaine Program home summaries.

Thank you for reading. Our goal is to support careful research and informed questions for people researching ibogaine.